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Increased expression of lymphangiogenesis factors VEGF-C/D and heparanase has been correlated with the invasion of cancer.
Furthermore, chemokines may modify matrix to facilitate metastasis, and they are associated with VEGF-C and heparanase. The
chemokine CXCL7 binds heparin and the G-protein-linked receptor CXCR2. We investigatedthe eﬀect of CXCR2 blockade on the
expression of VEGF-C/D, heparanase, and on invasion. CXCL7 siRNA and a speciﬁc antagonist of CXCR2 (SB225002) were used
to treat CXCL7 stably transfected MCF10AT cells. Matrigel invasion assays were performed. VEGF-C/D expression and secretion
were determined by real-time PCR and ELISA assay, and heparanase activity was quantiﬁed by ELISA. SB225002 blocked VEGF-
C/D expression and secretion (P<. 01). CXCL7 siRNA knockdown decreased heparanase (P<. 01). Both SB225002 and CXCL7
siRNA reduced the Matrigel invasion (P<. 01). The MAP kinase signaling pathway was not involved. The CXCL7/CXCR2 axis is
important for cell invasion and the expression of VEGF-C/D and heparanase, all linked to invasion.
1.Introduction
Breast cancer is the most common malignancy in women,
and metastasis is the number one cause of mortality in breast
cancer [1]. Breast cancer treatments that target the steps of
metastasis are needed. An important part of metastasis is
invasion [2, 3]. Invasion depends in part on degradation of
extracellular matrix (ECM) and interaction with molecules
formed in the process. Recently, increasing attention has
been paid to chemokines that may modify breast cancer
cells and the surrounding matrix to facilitate metastasis. Fur-
thermore, there is evidence that chemokines, VEGF-C, and
heparanase are interrelated in the process of invasion [4–6].
Increased expression of the lymphangiogenesis factors and
heparanase has been correlated with progressive disease in
certain cancers [6]. Peritumoral lymphangiogenesis involves
the secretion of speciﬁc glycoproteins designated vascular
endothelial growth factor C (VEGF-C) and (VEGF-D) that
act on lymphatic endothelium, and are components of an
established signaling system for tumor lymphangiogenesis
[7]. Increased lymph node metastases are correlated with
increased expression of VEGF-D and VEGFR3 by immuno-
histochemistry in invasive breast cancer [8].
Heparanase is an endo-β-glucuronidase that cleaves
heparan sulfate (HS) side chains of heparin sulfate pro-
teoglycan (HSPG). Heparanase activity has been correlated
with cell invasion associated with breast cancer metastasis, a
consequence of structural modiﬁcation of HS that alters the
extracellular matrix [9, 10]. However, classical mammalian
heparanase is an intracellular enzyme and is not speciﬁc
to metastatic sites [11–13]. Therefore, another source of
heparanase may come from chemokines which are secreted.
Chemokines are a family of small molecular weight
proteins. CXCL7 is a member of the CXC subfamily of
chemokines which can be further subdivided on the basis
of the presence of the tripeptide motif glutamate-leucine-
arginine(ELR).AllELR+-CXCchemokinesactthroughCXC
chemokine receptor type1 or type2 (CXCR1 and CXCR2)
[14]. CXCL7, has dual functions of heparin binding and is
a ligand to the G-protein linked receptor CXCR2 [15].2 Journal of Oncology
Until recently, CXCL7 gene expression was thought to
be restricted to cells within the megakaryocytic lineage
[16, 17], as well as to neutrophils and lymphocytes. Recent
reports have suggested that other cell types may produce
this chemokine as well [18–23]. Despite studies on increased
expression of CXCR2 in breast cancer, reports on CXCL7 in
breast cancer are limited.
Earlier studies from our laboratory have shown that
the malignant breast cancer cells express more CXCL7 than
premalignantMCF10ATcells.CXCL7-transfectedMCF10AT
breast cells have much higher heparanase activity than
premalignantMCF10ATcells.CXCL7-transfectedMCF10AT
cells are as invasive as malignant breast cancer cells [24]. In
addition, the expression of VEGF C and D is increased in
these transfectants [5].
Heparanase and the lymphangiogenesis factors VEGF-C
and VEGF-D are two important markers closely related to
the metastasic capabilty of breast cancer. In this paper, we
hypothesize that CXCL7 increases the expression of VEGF-
C, VEGF-D, and heparanase, and increases cell invasion via
CXCR2signaling,alllinkedtotumorlymphangiogenesisand
metastasis.
2. Methods
2.1. Cell Culture and Plasmid Stable Transfection. The
MCF10AT cells [25] were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM)/F 12 (1:1) containing 5% horse
serum, supplemented with 10μg/ml bovine insulin, EGF
(20ng/ml), hydrocortisone (0.5μg/ml), and cholera toxin
(100ng/ml). Cells were cultured at 37
◦Ci na5 %C O 2
atmosphere. All cell culture reagents were obtained from
Gibco (Grand Island, NY). Approximately, 1 × 106 cells/well
were plated in 6-well plates in medium containing 5%
horse serum to grow overnight to 60%–70% conﬂuency.
Transfection of the plasmid was performed by using Lipo-
fectamine 2000 (Invitrogen, USA). The cells were divided
intoblankcontrolgroup,negativecontrolgroup,andthetest
group. Only Lipofectamine 2000 was used for transfection
in the blank control group. Plasmid PEGFP-N1 was used
for transfection in the negative control group. Plasmid
PEGFP-N1-CXCL7 was used for transfection in the test
group.Thecellsweretransfectedwiththemixtureofplasmid
and Lipofectamine 2000 (1:3) in 2ml serum-free medium.
At 24 hours after transfection, the medium was replaced
by normal medium containing 5% FBS and antibiotics up
to 72 hours post-transfection. Since the MCF10AT cells
were transfected cells, G418 could not be used for the
selection of the stably transfected cell line. Therefore, we
submitted the cells for the ﬂow cytometry sorting by using
the EGFP antibody. The transfected cells were picked out for
subculture. For sh-RNA plasmid transfection we used the
same method the described above. The sh-PPBP plasmids
were purchased from ORIGENE (Rockville, MD).
2.2. In Vitro Invasion Assays. Brieﬂy, BioCoat Matrigel
invasion chambers (Becton-Dickinson, Bedford, MA) were
rehydratedaccordingtothemanufacturer’sinstructions.Cell
suspensions (2.5 × 105 c e l l sp e r2 m ls e r u m - f r e em e d i u m )
were added to the top chamber, and complete medium in the
lower chamber. For control, inserts without Matrigel were
used. The cells were allowed to invade the Matrigel at 37
◦C
in 5% CO2 for 48 hours. The noninvading cells on the upper
surface of membrane were removed from the chamber by
gentle scrubbing with a cotton swab, and the invading cells
on the lower surface of the membrane were stained with the
Quick-Diﬀ stain kit (Becton-Dickinson). After two washes
withwater,thechamberswereallowedtoairdry.Membranes
were mounted on glass slides and counted manually under
a light microscope. Cells were counted in ﬁve high power
ﬁelds (40x magniﬁcation). The number of invading cells was
expressed as a percentage by the following: the mean number
of the cells invading through the Matrigel insert membrane
dividedbythemeannumberofcellsmigratingundercontrol
insert membrane conditions multiplied by 100. All assays
were performed in triplicate.
2.3. Quantitative Real-Time PCR. RNA was extracted using
the RNeasy Mini Kit (catalog no. 74,804; Qiagen, Valencia,
CA), including treatment with DNase I to prevent genomic
DNA contamination using RURBO DNA-free Kit (catalog
no. AM1907; Ambion, Foster City, CA) according to the
manufacturer’s instructions. Total RNA (two micrograms)
was reverse-transcribed to cDNA by using the SuperScript
III First-Strand Synthesis System (catalog no. 18080-051;
Invitrogen, Carlsbad, CA), according to the manufacturer’s
protocol. Three replicate samples were used for the three
cell lines. The primer sequences used for the reactions
are in Table 1 along with expected products and GenBank
accession numbers. The thermocycler parameters were as
follows: an initial step at 95
◦Cf o r1 0m i n . ,4 0c y c l e so f9 5
◦C
for 20sec., 58
◦C for 30sec., and 72
◦C for 20 seconds. The
cycle threshold values were used to calculate the normalized
expression of VEGFC/D against β-actin. qRT-PCR was
performed in ABI 7500 Sequence Detection System using a
SYBR Green detection system (catalog no. 170- 8880; Bio-
RadLaboratories).Byidentifyingthethresholdcycle(CT)for
expression of mRNA, the ΔCT for VEGF-C/D was calculated
and compared to vector transfected control cells; CXCL7
transfected cells and SB225002-treated CXCL7 transfected
cells.TheΔCT wasconvertedintoaratio(targetA/targetB =
2−ΔCT) describing the comparison of the relative expression
of VEGF-C/D (target A) to β-actin (target B) for each of
the lines. The Delta-delta model was used for comparison of
relative expression RT-PCR results for VEGF-C/D.
2.4. Protein Quantiﬁcation. VEGF-C and VEGF-D protein
concentrations in conditioned media were measured by
enzyme-linked immunosorbent assay (ELISA) using human
VEGF-C or VEGF-D ELISA Development System (catalog
no. DVEC 00 and DVED00, R&D Systems, Minneapolis,
MN). Measurements were done at least in duplicate for 2
dilutions. The optical density at 570nm and 450nm was
determined for each well using the plate reader. Then the
readingat570nmwassubtractedfromthereadingat450nm
for each well.Journal of Oncology 3
Table 1: Summary of primers for Real-Time PCR.
Gene: VEGF-C
GenBank Accession No.: NM 005429
Product size: 128bp
Primers:
Forward: 5 -GCCACGGCTTATGCAAGCAAAGAT-3 
Reverse: 5 -AGTTGAGGTTGGCCTGTTCTCTGT -3 
Gene: VEGF-D
GenBank Accession No.: NM 004469
Product size: 132bp
Primers:
Forward: 5 -CGATGTGGTGGCTGTTGCAATGAA -3 
Reverse: 5 -GCTGTTGGCAAGCACTTACAACCT -3 
Gene: beta-actin
GenBank Accession No.: X00351
Product size: 125bp
Primers:
Forward: 5 -GGACTTCGAGCAAGAGATGG-3 
Reverse: 5 - AGCACTGTGTTGGCGTACAG -3 
2.5. Heparanase Activity Measurement. The protein concen-
trationoftheserum-freeconditionedmediumwasmeasured
by the Bradford assay (BioRad, Richmond, CA, USA). The
heparanase activity of the conditioned medium was assessed
as heparan sulfate degrading enzyme activity using the
Heparan Degrading Enzyme Assay Kit (catalog no. MK412,
Takara, Ootsu, Japan). The duration of a series of assays was
100min., including 45min. of enzyme degradation reaction.
One unit of heparanase activity deﬁned the activity which
degraded 0.063ng of biotinylated heparin sulfate in 1min.
at 37
◦C and pH 5.8. The detection limit of this assay was
0.1U/mL. Each value of heparanase activity was normalized
by protein concentration (U/g protein).
2.6. Western Blotting. Cells were processed for protein
extraction and western blotting using standard procedures.
Brieﬂy, the cells were harvested in PBS, counted, and
lysed in the RIPA buﬀer (catalog no. R0278, SIGMA, St.
Louis, MO) with protease inhibitor cocktail (catalog no.
P8340, SIGMA, St. Louis, MO), and samples were kept at
4◦C. Protein concentration was determined for all samples
using the Bio-Rad protein assay (catalog no. 500-0006, Bio-
Rad, Richmond, CA). The equal-volume samples (50μg)
were separated by SDS-PAGE on a 10% polyacrylamide
gel and transferred onto nitrocellulose membrane (catalog
no. 162-0114, Bio-Rad, Richmond, CA) using transfer tank.
Immunodetection was performed using pERK1/2 (catalog
no. 9101, Cell Signaling Technology) and ERK1/2 (catalog
no.9102, Cell Signaling Technology), then developed by ECL
(catalog no. PRN 2106, GE Healthcare, Waukesha, WI) and
was photodocumented.
2.7. Statistical Analysis. Results are expressed as mean ±
standard error of the mean (SEM), unless indicated other-
wise. For statistical analysis, one-way ANOVA was used, and
signiﬁcance was deﬁned as P<. 05. Graphs were generated
using GraphPad Prism (GraphPadSoftware,San Diego, CA).
3. Results
3.1. CXCR2 Antagonist SB225002 Reduced Invasion of
Matrigel by Stably CXCL7-Transfected MCF10AT Cells. To
further verify CXCL7 function in cell invasion, a selective
nonpeptide CXCR2 antagonist SB225002 [26]w a su s e d
to check whether it can inhibit the invasive ability of
MCF10AT cells transfected with CXCL7. MCF10AT cells
were stably transfected with CXCL7 plasmid. After 48 hours
of incubation, cells were added into the Matrigel invasion
chamber; meanwhile, SB225002 (1.1μM) was also added
into the chamber. Several concentrations of SB225002 were
tested (0.5, 0.7, 0.9, 1.1, 1.3, and 1.5μM) and 1.1μM had the
best inhibitory eﬀect similar to that reported by Levashove
et al. [23]. After 48 hours, cells were ﬁxed and stained
with Diﬀ-Quick. The decrease in the percent invasion of
Matrigel by the cells is shown in Figure 1 .T r e a t m e n tw i t h
SB225002resultedin18.06%±0.76%invasivecellscompared
with 55.7% ± 1.4% in nontreated CXCL7 stable transfected
MCF10AT cells. Thus, the CXCR2 antagonist blocked the
invasive ability of CXCL7 stably transfected MCF10AT cells.
3.2. Expression and Secretion of Lymphangiogenesis Fac-
tor VEGF-C and VEGF-D by Stable CXCL7 Transfected
MCF10AT Cells Are Blocked by SB225002. To investigate the
eﬀect of SB225002 on expression and secretion of VEGF-C
and VEGF-D by stable CXCL7-transfected MCF10AT cells,
we cultured the cells with and without SB225002 (1.1μM).
After 48-hour treatment, the media and the cells were
collected. Expression of mRNA for lymphangiogenic factors
VEGF-C and VEGF-D was determined by quantitative
real-time polymerase chain reaction (qRT-PCR) assay. The
expression levels of mRNAs for VEGF-C, VEGF-D, are
showninFigure 2(a).β-actinwasusedasaninternalcontrol.
Compared with vector-transfected MCF10AT cells, CXCL7-
transfected MCF10AT cells showed 11-fold higher VEGF-
C and 18-fold higher VEGF-D expression. Administration
of SB225002 antagonist resulted in a signiﬁcant (P<
.01) inhibition of VEGF-C (3.5-fold) and VEGF-D (3-fold)
mRNA expression. Next, we examined the secretion of the
VEGF-C and VEGF-D by ELISA assay. The secretion levels
of VEGF-C, VEGF-D are shown in Figure 2(b).B o t hV E G F -
C and VEGF-D secretion from the CXCL7-transfected cells
were signiﬁcantly (P<. 01) increased compared with the
vector-transfected control group (VEGF-C, 3-fold; VEFG-
D, 2.5-fold). Our data also showed a signiﬁcant (P<. 05)
inhibition in VEGF-C and VEGF-D secretion by SB225002-
treated cells compared with control treated cells. Thus the
CXCR2 antagonist decreases VEGF-C and VEGF-D mRNA
and protein expression.
3.3. CXCL7 siRNA Inhibited Heparanase Activity and Inva-
sion of CXCL7 Stably Transfected Cells. Next, we examined
whether CXCL7 siRNA inhibited the elevated heparanase4 Journal of Oncology
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Figure 1: CXCR2 antagonist SB225005 reduced the invasion of MCF10AT stably transfected with CXCL7 using a BD BioCoat Matrigel
invasion assay (6-well plates), 1.25 x 105 cells/ml were inoculated onto the membrane in serum-free medium. For the blocking experiment,
there was serum-free medium containing SB225002 (1.1μM) in the upper chamber. The lower chamber contained complete medium, and
the control membrane did not have Matrigel by which to measure the migration of cells. After 48 hours, membranes were ﬁxed, stained, and
photographed, then the percent invasion was determined. Triplicate assays were done. Results are reported per cell line as percent invasion
± (mean number of cells invading Matrigel membrane/mean number of cells migrating through control membrane) ×100 (P<. 01).
(Upper) SB225002 signiﬁcantly decreased the invasion of CXCL7-stable transfected MCF10AT cells compared with notreated cells. (Lower)
Membranes were stained by Diﬀ-Quik kit and were photographed (original magniﬁcation x 20).
activity of CXCL7-stably transfected cells. Cells were trans-
fected with CXCL7 siRNA or control siRNA, and after
48 hours, the CM was collected. Compared with control
siRNA treatment, CXCL7 siRNA-transfected cells showed
signiﬁcant (P<. 01) inhibition of heparanase enzymatic
activity (Figure 3(a)). The same results were obtained after
using a Microcon ﬁlter to remove molecules less than 30kD
(which includes CXCL7) from CM, verifying by ELISA that
CXCL7 is not present after ﬁltering. And then, retesting for
heparanase activity were performed.
To further conﬁrm the increased invasion after trans-
fection by CXCL7, we used the CXCL7 siRNA to block
the CXCL7 signal. Matrigel invasion assays were performed
with cells transfected with CXCL7 siRNA or control siRNA.
The decrease in the percent invasion of Matrigel by the
cells is shown in Figure 3(b). Treatment with siRNA resulted
in 16% ± 1.2% invasive cells compared with 37% ± 2.5%
by MCF10AT cells transfected with CXCL7. Thus, CXCL7
siRNA inhibits the invasion of MCF10AT cells transfected
with CXCL7.
3.4. Expression and Secretion of Lymphangiogenesis Fac-
tor VEGF-C and VEGF-D by Stable CXCL7 Transfected
MCF10AT Cells Are Silenced by sh-PPBP Transfection. To
further conﬁrm the increased expression and secretion of
lymphangiogenesisfactorsVEGF-CandVEGF-Daftertrans-
fectionbyCXCL7,weusedthesh-PPBPtosilencetheCXCL7
signal. To investigate the eﬀect of sh-PPBP on expression and
secretion of VEGF-C, VEGF-D of stable CXCL7-transfected
MCF10AT cells, we cultured the cells transfected with sh-
PPBP or control (sh-con). After 48 hours of transfection,
the media and the cells were collected. Expression of the
mRNA of lymphangiogenic factors VEGF-C and VEGF-D
was determined by quantitative real-time polymerase chain
reaction (qRT-PCR) assay. The expression levels of mRNAs
for VEGF-C, VEGF-D, are shown in Figure 4(a). β-actin
was used as an internal control. Compared with vector-
transfected MCF10AT cells, CXCL7-transfected MCF10AT
cells showed 11-fold higher VEGF-C and 18-fold higher
VEGF-D expression. The sh-PPBP transfection resulted in a
signiﬁcant (P<. 01) silencing of VEGF-C (66%) and VEGF-
D(68%)mRNAexpression.Next,weexaminedthesecretion
of the VEGF-C and VEGF-D by ELISA assay. The secretion
levels of VEGF-C, VEGF-D are shown in Figure 4(b).B o t h
VEGF-CandVEGF-DsecretionfromtheCXCL7-transfected
cellsweresigniﬁcantly(P<. 01)increasedcomparedwiththe
vector-transfected control group (VEGF-C, 3.3-fold; VEFG-
D, 4.4-fold). Our data also showed a signiﬁcant (P<. 05)
silencing in VEGF-C (65%) and VEGF-D (68%) secretion by
sh-PPBP transfected cells compared with sh-con transfected
cells.
3.5. ERK1/2 Mitogen-Activated Protein Kinase Pathway Is
not Involved in CXCL7-CXCR2-Mediated Stimulation of
Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast
Cancer Cells. The MAP kinase pathway is important for
growth, diﬀerentiation, and migration, and is considered
a dominant signaling pathway for CXCR2 [27, 28]. To
investigate the mechanism by which the CXCL7-CXCR2
axis is involved in the stimulation of lymphangiogenic
factors VEGF-C, VEGF-D toward invasion by human breast
cancer cells, we investigated the involvement of ERK1/2Journal of Oncology 5
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Figure 2: SB225005 blocked VEGF-C and VEG-D mRNA expression by CXCL7-transfected MCF10AT cells. CXCL7-stably transfected
MCF10AT cells were cultured with and without SB225002 (1.1μM). After 48-hour treatment, the media and the cells were collected. (a)
Quantitative analysis of VEGF-C and VEGF-D mRNA expression. Total RNA was extracted, and real-time qRT-PCR was performed. β-actin
was applied as internal control. Triplicate determinations were performed. The diﬀerences between the cell lines were signiﬁcant (P<. 01).
(b) Quantitative analysis of VEGF-C and VEGF-D protein secretion by the CXCL7-stable transfected MCF10AT cells. Protein concentration
in CM was measured by ELISA using human VEGF-C and VEGF-D ELISA Development System. Measurements were done at least in
duplicate for 2 dilutions. The optical density of each well was determined using plate reader by subtracting the reading at 570nm from the
reading at 450nm. VEGF-C/D content in CM of SB225002-treated group was signiﬁcantly lower than untreated group (P<. 05).
MAP kinases by western blotting. Stable CXCL7-transfected
MCF10AT cells did not induce ERK1/2 phosphorylation in
comparison with the vector transfected control cells, and
there is no diﬀerence in ERK1/ 2 MAP kinase expression in
stableCXCL7transfectedMCF10ATcellscomparedtovector
controls (Figure 5).
4. Discussion
Although many molecules have been implicated in cancer
metastasis, the detailed mechanism of tumor metastasis is
still not completely understood. Recently, the interest in
chemokines in cancer research has been increasing as new
chemokines are being identiﬁed and investigated. Working
along with many other molecules, the chemokines and
their receptors expressed by both the cancer and its stroma
inﬂuence growth, dormancy, angiogenesis, and invasion [3,
6, 29]. The CXCR4/CXCL12 (SDF-1) axis was the most
common interaction that has been shown to be involved in
manydiﬀerenthumanmalignancies,includingbreastcancer,
ovarian cancer, and prostate cancer [30, 31]. However,
CXCR4 interactions alone did not completely explain the
pattern of metastasis of cancer.
There are 4 families of chemokines (C, CC, CXC,
and CX3C) based on the arrangement of cysteine residues
near the N terminus [32, 33]. The CXC group can be
further subdivided on the basis of presence of the tripeptide
motif glutamate-leucine-arginine (ELR) adjacent to the
CXC motif. All ELR+-CXC chemokines act through CXC
chemokine receptor type 1 or type 2 (CXCR1 or CXCR2),
whicharetransmembraneG-protein-coupledreceptors[32].
ELR+-CXC chemokines can stimulate angiogenesis. Those
without the ELR motif inhibit angiogenesis [34, 35]. Secre-
tion of stromal cell-derived factor-1 (SDF-1)/CXCL12 and
expression of CXCR4 have been identiﬁed to be associated
with breast cancer metastasis [36]. Although CXCR4 was
more highly expressed in the breast cancer cells tested by6 Journal of Oncology
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Figure 3: CXCL7 siRNA decreased heparanase activity and invasion of CXCL7-stably transfected cells. The CXCL7 MISSION siRNA was
used to eﬀectively knockdown heparanase activity and the invasion of CXCL7-stably transfected cells while the nontargeting siRNA was used
as a control. CXCL7-stable transfected MCF10AT cells (2 × 105) were transfected with 100pmol of each siRNA by using the Lipofectamine
2000 transfection reagent (Invitrogen) after 48 hours in culture. (a) Quantifying heparanase activity. The CM was collected 24 hours later
and analyzed by heparanase-degrading enzyme assay kit. Indicated amounts of cell lysate were incubated with biotinylated heparan sulfate
at 37
◦C for 45 minutes, and enzyme activity was determined using an ELISA-type assay. Color was developed using the substrate supplied in
the kit, and plates were read at 450nm using a microplate reader. Decreased heparanase activity in CXCL7 siRNA. (b) Invasion of Matrigel.
Using a BD BioCoat Matrigel invasion assay (6-well plates), 1.25×105 cells/ml were inoculated onto the membrane in the upper chamber in
serum-free medium. The lower chamber contained complete medium, and control membrane did not have Matrigel to measure migration
of cells. Triplicate assays per group were completed. Results reported per cell line as % invasion = (mean number of cells invading Matrigel
membrane/mean number of cells migrating through control membrane) ×100. CXCL7 siRNA signiﬁcantly inhibited the invasion of CXCL7
stable transfected MCF10AT cell, while the control siRNA did not. Results compared by one-way ANOVA (P<. 01).
M¨ uller et al. [37] than the other CXCRs, the expression
of CXCR2 was also increased compared with the remain-
ing receptors. CXCL7, which is a member of the ELR-
CXC chemokines, binds with CXCR2 receptors, stimulating
angiogenesis and association with neutrophils and other
immunecomponents[38].InhibitionofCXCR2functionon
endothelialcellshasbeenshowntoinhibittumorgrowth,for
lung cancer and renal cell cancer models [39, 40].
The use of a small selective antagonist for CXCR2
(SB225002) represents an attractive targeted therapeutic
approach [26]. Previous work in our laboratory showed that
breast cancer cells coexpress CXCL7 and CXCR2, which may
act as a potential autocrine mechanism in breast cancer.
The malignant cell line MCF10CA1a.cl1 strongly expressed
CXCL7 and has much higher invasive ability than MCF10AT.
MCF10AT cells gained invasive ability after they were trans-
fected with CXCL7. Thus, CXCL7-transfected MCF10AT
cells were as invasive as malignant cells, suggesting that
CXCL7 may have a role in the invasion process. Therefore,
targeting its receptor, CXCR2, seemed an obvious choice.
By using CXCL7-stably transfected MCF10AT cells
treated by SB225002, invasion was decreased signiﬁcantly
compared with CXCL7-transfected cells, which might
involve CXCL7 autocrine activity with CXCR2. The present
study did not examine whether SB225002 could block the
invasive ability of isogenic malignant cells (MCF10CA1a.cl1)
or other malignant cell lines, which would be an interesting
focus for future study.
Lymphangiogenesis refers to the formation of new lym-
phatic vessels that may occur in normal developing tissues
or in tumors. Overexpression of VEGF-C or VEGF-D can
lead to lymphangiogenesis, intralymphatic tumor growth
and formation of lymph node metastases [41, 42]. VEGF-
C and VEGF-D are ligands for VEGFR-3 (also termed fms-
like tyrosine kinase 4, Flt-4), a tyrosine kinase receptor
that is expressed predominantly in lymphatic endothelial
cells [43]. The breast cancer cells secrete VEGF-C, VEGF-
D which directly interact with the receptor. This paracrine
relationship may lead to further changes in the breast
cancer cells leading to invasion. Chemokine and VEGF-C
interactions have been reported in a model of cross-talk
for lymphatic endothelial cells and melanoma cells [4]. In
our study, both the selective CXCR2 antagonist and sh-
PPBP suppresses the elevated expression and secretion of
VEGFC/D by the CXCL7-transfected MCF10AT cells. These
results support the notion that the CXCL7/CXCR2 axis plays
an important role in cancer cell lymphangiogenesis.
The chemokine connective tissue-activating peptide
(CTAP-III), which is an N-truncated derivative of CXCL7,
has been reported to have heparanase activity [15, 44].
The heparanase activity of chemokines may be important
for modiﬁcation of matrix [15]. Heparanase activity is
also responsible for the egress of metastatic tumor cells
and other blood-borne cells from the vasculature. Inhibi-
tion of heparanase activity results in decreased metastasis.
Recently, expression of VEGF-C was shown to be inducedJournal of Oncology 7
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Figure 4:Thesh-PPBPsuppressVEGF-Cand VEGF-DmRNA expression and secretion byCXCL7-transfectedMCF10ATcells. We cultured
the cells transfected with sh-PPBP or control sh-con. After 48 hours treatment, the media and the cells were collected. (a) Quantitative
analysisofVEGF-CandVEGF-DmRNAexpression.TotalRNAwasextracted,andreal-timeqRT-PCRwasperformed.β-actinwasappliedas
internal control. Triplicate determinations were performed. The diﬀerences between the cell lines were signiﬁcant (P<. 01). (b) Quantitative
analysis of VEGF-C and VEGF-D protein secretion by the CXCL7 stable transfected MCF10AT cells. Protein concentration in CM was
measured by ELISA using human VEGF-C and VEGF-D ELISA Development System. Measurements were done at least in duplicate for
2 dilutions. The optical density of each well was determined using plate reader by subtracting the reading at 570nm from the reading at
450nm. VEGF-C and VEGF-D content in CM of sh-PPBP-transfected group was signiﬁcantly lower than the control group (P<. 05).
by heparanase in prostate cancer cells, epidermoid can-
cer cells, breast cancer cells, and melanoma [6]. In this
study, heparanase activity in the CM of CXCL7-transfected
MCF10AT cells was tested, and it was determined that
theCXCL7-transfectedcellsdemonstratedincreasedsecreted
heparanase activity. This elevated activity was inhibited
by CXCL7 siRNA. In addition, silencing CXCL7 inhibited
the invasive ability of CXCL7-transfected MCF10 AT cells
which further elucidates its role in invasion. The expression
of VEGF-C and VEGF-D mRNA and protein was also
decreased in these transfectants by shRNA, thus linking
the expression of the chemokine CXCL7 to VEGF-C and
VEGF-D, heparanase expression, and invasive ability. The
MCF10 model of progressive breast disease provides isogenic
cell lines with increasing malignant potential to study the
steps of metastasis. Additional breast cancer cell lines and
breast cancer tissue can be tested speciﬁcally for CXCL7
expression and eﬀects on lymphangiogenesis, heparanase
expression and invasion in the future. Lymphangiogenesis in
human breast cancer samples can be correlated with clinical
parameters and CXCL7/CXCR2 staining.
To explain the mechanism by which the CXCL7-
CXCR2 axis is involved in the stimulation of lymphan-
giogenic factors VEGF-C, VEGF-D, increased invasion and
heparanase expression in human breast cancer cells. We
investigated the MAP kinase signaling pathway [45, 46].
We demonstrated that CXCL7-stable transfected MCF10AT
cells do not activate ERK1/2 MAP kinase signaling. We
did not observe a diﬀerence of ERK1/2 kinase in CXCL7-
stable transfected MCF10AT cells compared with control
cells. This result suggests the involvement of diﬀerent
pathways other than MAP kinase signaling for the CXCL7-
CXCR2 axis activation. In general, the activation of G-
protein coupled receptors (GPCRs) like CXCR2 leads to
the dissociation of the α subunit from the β,γ-dimer
when GDP is replaced by GTP [47]. Both subunits can
activate many signaling pathways including phospholipase C
and adenyl cyclase. When speciﬁcally considering CXCR2,
information from CXCL8 might shed some light on other
potential pathways for CXCL7 since these two chemokines
have 48% identity in their amino acid sequences and both
bind CXCR2 [48]. CXCL8 binding to CXCR2 activates8 Journal of Oncology
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Figure 5: ERK1/2 mitogen-activated protein kinase is not active
in CXCL7 stable transfected MCF10AT cells. Brieﬂy, the cells were
harvested in PBS, counted and lysed in the RIPA buﬀer with
protease inhibitor cocktail. Protein concentration was determined
for all samples using the Bio-Rad protein assay. The equal-
volume samples (50μg) were separated by SDS-PAGE on a 10%
polyacrylamide gel and transferred onto nitrocellulose membrane.
Immunodetection was performed using pERK1/2 and ERK1/2,
then developed by ECL. Stable CXCL7 transfected MCF10AT cells
did not induce ERK1/2 phosphorylation compared to the vector
transfected control cells. Furthermore, the expression of ERK1/2
wasthesameinstableCXCL7transfectedMCF10ATcellscompared
to vector controls.
the Rac/PI3K, Rho and Ras pathways [49]. Therefore, the
CXCL7/CXCR2 axis may activate pathways other than the
MAP kinase pathway, including Rac/PI3K, Rho and Ras
pathways.
5. Conclusions
In the present paper we showed that both the selective
CXCR2 antagonist SB225002 and sh-PPBP suppress VEGF-
C, VEGF-D expression and secretion in CXCL7-transfected
MCF10AT cells. Furthermore, we also observed that both
SB225002 and CXCL7 siRNA reduced the invasion of
CXCL7-stably transfected MCF10AT cells, conﬁrming the
role of the CXCL7/ CXCR2 axis in cell invasion, possibly
through the receptor’s signaling mechanism. However,
this does not involve the MAP kinase signaling pathway as
has been described for other ELR+ CXC chemokines like
IL-8. It has also been shown that CXCL7 siRNA knocked
down heparanase activity in transfected MCF10AT cells,
suggesting an important role for CXCL7 in heparanase
expression. Taken together, these data would support
that the CXCL7/CXCR2 axis may be important in breast
cancer metastasis. Therapeutics aimed at antagonizing CXC
chemokine action, including CXCL7, may be beneﬁcial in
preventing invasion and thus the spread of breast cancer.
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